Pharmacogenomics of antiretrovirals

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 2, 2008, Pages 132-135

  Roca, Bernardino ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b NONE   (Spain)

Author keywords

Antiretrovirals; HIV; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450 2B6; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; INDINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; BENZOXAZINE DERIVATIVE; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; HLA ANTIGEN; N DEMETHYLASE; OLIGOPEPTIDE; PYRIDINE DERIVATIVE; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ABDOMINAL PAIN; AGITATION; AMNESIA; ANAPHYLAXIS; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHILL; CONFUSION; COUGHING; DEPERSONALIZATION; DIARRHEA; DIZZINESS; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; EUPHORIA; FATIGUE; FEVER; GENETIC RISK; GENETIC VARIABILITY; HALLUCINATION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSOMNIA; JAUNDICE; KIDNEY TUBULE DISORDER; LIPOATROPHY; MALAISE; MENTAL CONCENTRATION; MYALGIA; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SORE THROAT; TACHYPNEA; THINKING IMPAIRMENT; UNPLEASANT DREAM; VOMITING; ANTIVIRAL RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG HYPERSENSITIVITY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; IMMUNOLOGY; PATENT; PATIENT SELECTION; PHARMACOGENETICS; REVIEW;

ANTI-RETROVIRAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CENTRAL NERVOUS SYSTEM DISEASES; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, VIRAL; DYSLIPIDEMIAS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GLUCURONOSYLTRANSFERASE; HLA ANTIGENS; HUMANS; HYPERBILIRUBINEMIA; NEVIRAPINE; OLIGOPEPTIDES; OXIDOREDUCTASES, N-DEMETHYLATING; PATENTS AS TOPIC; PATIENT SELECTION; PHARMACOGENETICS; PYRIDINES; RITONAVIR;

EID: 52449096339     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108784746650     Document Type: Article

References (39)

1. Fontanarosa PB, Pasche B, DeAngelis CD. Genetics and genomics for clinicians. JAMA 2008; 299: 1364-1365.
2. Daly AK. Pharmacogenetics and pharmacogenomics. Pharmacogenomics 2007; 8: 1493-1496.
3. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193.
4. Reynolds GP. The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov Today 2007; 12: 953-959.
5. Gumbo T. Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy. Curr Opin Drug Discov Devel 2008; 11: 32-42.
6. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008; 358: 637-639.
7. DHHS Panel on antiretroviral guidelines for adults and adolescents. guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008. Available at: http://aidsinfo.nih.gov/.
8. Phillips EJ, Mallal SA. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. Curr Opin Infect Dis 2008; 21: 16-24.
9. Ma Q, Brazeau D, Forrest A, Morse GD. Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics 2007; 8: 1169-1178.
10. Telenti A, Zanger UM. Pharmacogenetics of Anti-HIV Drugs. Annu Rev Pharmacol Toxicol 2008; 48: 227-256.
11. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update (March) (CE). Ann Pharmacother 2008 Feb 26.
12. *5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45: 1-3.
13. *5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res Hum Retroviruses 2007; 23: 1374-1376.
14. *5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
15. *5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 2007; 60: 599-604.
16. *5701 clinical testing: early experience in the United States. Pharmacogenet Genomics 2007; 17: 857-860.
17. Hammond E, Almeida C, Mamotte C, et al. External quality assessment of HLA-B_5701 reporting: an international multicentre survey. Antivir Ther 2007; 12: 1027-1032.
18. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19: 979-981.
19. Walker, M.A, Li, C, Grantyoung, K.A., Matiskella, J.D., Naidu, B N., Banville, J., Beaulieu, F., Ouellet C., Pendri, A., Remillard, R., Ueda, Y., Yin, T. T.: WO08002959 (2008).
20. Kennedy-Smith, J., Palmer, W.S., Sweeney, Z.K.: WO08019968 (2008).
21. Sweeney, Z.K.: WO08009613 (2008).
22. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, et al. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res 2008; 6: 65-69.
23. Taiwo BO. Nevirapine toxicity. Int J STD AIDS 2006; 17: 364-369.
24. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21:264-265.
25. *01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22: 540-541.
26. Allaway, G., Kilgore, N., Wild, C.T.: US20080039428 (2008).
27. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192: 1381-1386.
28. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44: 1324-1332.
29. Vrouenraets SM, Wit FW, van Tongeren J, Lange JM. Efavirenz: a review. Expert Opin Pharmacother 2007; 8: 851-871.
30. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 2007; 8: 547-558.
31. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81: 557-566.
32. *26. Clin Infect Dis 2007; 45: 1230-1237.
33. Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: An Adult AIDS Clinical Trials Group study. Pharmacogenet Genomics 2006; 16: 837-845.
34. Arnedo M, Taffe P, Sahli R, et al. Evaluation of the contribution of 20 variants of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007; 17: 755-764.
35. Felley C, Morris MA, Wonkam A, et al. The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS 2004; 18: 1521-1527.
36. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-1491.
37. Josephson F, Allqvist A, Janabi M, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007; 81: 708-712.
38. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003; 17:121-123.
39. *LHON4917G and antiretroviral therapy associated peripheral neuropathy. Pharmacogenomics J 2008; 8: 71-77.